Overview

A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Treatments:
Gemcitabine
Criteria
Inclusion Criteria:

- all proven to have locoregional recurrence after curative treatment and unsuitability
for further local treatment, distant metastases at presentation or acquired metastases
after curative treatment. the presence of at least one measurable disease, which was
defined as lesion that could be measured at least 20 mm in one dimension by
conventional computed tomography (CT) or at least 10 mm by spiral CT scan; KPS≥70, and
a life expectancy of at least 6 months.

Exclusion Criteria:

- other malignancy prior to study entry; bone-only metastasis;previous radiotherapy
within 4 weeks; previous exposure to gemcitabine;patients with any active,
non-controlled infection or other severe systemic diseases, such as congestive heart
failure, angina pectoris, respiratory insufficiency and arrhythmia were all rejected
at enrollment. Other exclusion criteria included concurrent treatment with other
investigational drugs, hypersensitivity to platinum compounds,and current pregnancy or
breastfeeding.